» Articles » PMID: 14522969

Reprogramming Alternative Pre-messenger RNA Splicing Through the Use of Protein-binding Antisense Oligonucleotides

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Oct 3
PMID 14522969
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Alternative pre-messenger RNA splicing is a major contributor to proteomic diversity in higher eukaryotes and represents a key step in the control of protein function in a large variety of biological systems. As a means of artificially altering splice site choice, we have investigated the impact of positioning proteins in the vicinity of 5' splice sites. We find that a recombinant GST-MS2 protein interferes with 5' splice site use, most efficiently when it binds upstream of that site. To broaden the use of proteins as steric inhibitors of splicing, we have tested the activity of antisense oligonucleotides carrying binding sites for the heterogeneous nuclear ribonucleoprotein A1/A2 proteins. In a HeLa cell extract, tailed oligonucleotides complementary to exonic sequences elicit strong shifts in 5' splice site selection. In four different human cell lines, an interfering oligonucleotide carrying A1/A2 binding sites also shifted the alternative splicing of the Bcl-x pre-mRNA more efficiently than oligonucleotides acting through duplex formation only. The use of protein-binding oligonucleotides that interfere with U1 small nuclear ribonucleoprotein binding therefore represents a novel and powerful approach to control splice site selection in cells.

Citing Articles

From computational models of the splicing code to regulatory mechanisms and therapeutic implications.

Capitanchik C, Wilkins O, Wagner N, Gagneur J, Ule J Nat Rev Genet. 2024; 26(3):171-190.

PMID: 39358547 DOI: 10.1038/s41576-024-00774-2.


Optimization of Bifunctional Antisense Oligonucleotides for Regulation of Mutually Exclusive Alternative Splicing of Gene.

Bartys N, Pasternak A, Lisowiec-Wachnicka J Molecules. 2022; 27(17).

PMID: 36080449 PMC: 9457596. DOI: 10.3390/molecules27175682.


Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease.

Marabti E, Abdel-Wahab O Trends Mol Med. 2021; 27(7):643-659.

PMID: 33994320 PMC: 8238868. DOI: 10.1016/j.molmed.2021.04.005.


Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease.

Sune-Pou M, Limeres M, Moreno-Castro C, Hernandez-Munain C, Sune-Negre J, Cuestas M Front Genet. 2020; 11:731.

PMID: 32760425 PMC: 7373156. DOI: 10.3389/fgene.2020.00731.


Alternative Splicing as a Target for Cancer Treatment.

Martinez-Montiel N, Rosas-Murrieta N, Anaya Ruiz M, Monjaraz-Guzman E, Martinez-Contreras R Int J Mol Sci. 2018; 19(2).

PMID: 29439487 PMC: 5855767. DOI: 10.3390/ijms19020545.